 | • レポートコード：B-MOR-08297 • 出版社/出版日：Mordor Intelligence / 2018年6月1日 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、鉄欠乏性貧血治療の世界市場について調べ、鉄欠乏性貧血治療の世界規模、市場動向、市場環境、治療タイプ別（経口鉄剤療法、非経口鉄剤療法、赤血球輸血、その他）分析、エンドユーザー別（病院、診療所、在宅医療）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・鉄欠乏性貧血治療の世界市場インサイト ・鉄欠乏性貧血治療の世界市場環境 ・鉄欠乏性貧血治療の世界市場動向 ・鉄欠乏性貧血治療の世界市場規模 ・鉄欠乏性貧血治療の世界市場規模：治療タイプ別（経口鉄剤療法、非経口鉄剤療法、赤血球輸血、その他） ・鉄欠乏性貧血治療の世界市場規模：エンドユーザー別（病院、診療所、在宅医療） ・鉄欠乏性貧血治療の世界市場：地域別市場規模・分析 ・鉄欠乏性貧血治療の北米市場規模・予測 ・鉄欠乏性貧血治療のアメリカ市場規模・予測 ・鉄欠乏性貧血治療のヨーロッパ市場規模・予測 ・鉄欠乏性貧血治療のアジア市場規模・予測 ・鉄欠乏性貧血治療の日本市場規模・予測 ・鉄欠乏性貧血治療の中国市場規模・予測 ・鉄欠乏性貧血治療のインド市場規模・予測 ・鉄欠乏性貧血治療の韓国市場規模・予測 ・関連企業情報・競争状況 |
The global iron deficiency anemia therapy market is expected to register a CAGR of 7.2% during the forecast period, 2018 to 2023. Iron deficiency anemia is caused due to the lack of iron, which is one of the most common types of anemia. In case of women, in the child bearing age, iron loss in the blood is due to heavy menstruation or pregnancy. Certain intestinal diseases and poor diet can also cause anemia.
Rising Cases of Haemodilution in Pregnancy
Haemodilution is a condition in which there is decreased concentration of cells and solids in the blood. It is caused due to Plasma Volume Expansion (PVE). The PVE is dependent on various factors, like weight of the mother, BMI, hormonal state of the mother during pregnancy, etc. The cases of haemodilution are rising due to changes in lifestyles, such as lack of exercise, fast food, smoking, etc. These lifestyle changes are more in developed and developing countries, which is resulting in irregular BMI, increase in abnormal weight, and also hormonal imbalance. Such factors result in disturbed physiology of a pregnant woman.
As per the statistics of American Heart Association, around 44 million women are affected by cardiovascular disease in the United States, and 90% of the women have one or more risk factors associated with heart disease. Therefore, rising cases of haemodilution is fueling the iron-deficiency anemia therapy market, globally. The other factors, such as high prevalence of anemia are also driving the iron deficiency anemia therapy market to grow.
Stringent Regulatory Guidelines
Anemia is a highly prevalent disease, for which the need for drugs has grown. However, due to strict regulatory guidelines, there are some drugs that are unable to enter the market. The approval of iron-deficiency drugs, which are highly important in the market, is time consuming, moreover, the process involved is stringent. There are some cases where a drug is approved but, due to side effects or ethical issues related to its use, the market for the same does not grow because of strict regulations of regulatory authorities. Also, the fee for approval and investment in R&D are quite high for these drugs. United States FDA has increased the fee for Abbreviated New Drug Approval (ANDA), by over USD 100,000 to USD 170,000 for FY 2018. The hike was approved as per the Generic Drug User Fee Amendments of 2017 (GDUFA II). This increase in approval fees is expected to restrain the iron-deficiency anemia therapy market. The other factors, such as side effects of drugs or supplements are also hindering the growth of the market.
United States Lead the Market in North America Region
The United States iron deficiency anemia therapy market held the largest market share in 2017 in North America region due to the presence of high quality healthcare system and the prevalence of anemia is a significant public health indicator and has remained a relevant health concern in the United States. A high prevalence of iron-deficiency anemia in US infants was first widely noted during the 1990s. Later on, the prevalence rate did not drop, making iron deficiency a significant public health problem in the United States.
Key Developments in the Market:
• February 2018 – Allergan acquired Elastagen, a manufacturer of skin augmentation products
• February 2018 – AMAG Pharmaceuticals announced FDA approval of supplemental new drug application (sNDA) for Feraheme® (ferumoxytol injection)
The major players include – ALLERGEN, AKEBIA THERAPEUTICS, AMAG PHARMACEUTICALS, KERYX BIOPHARMACEUTICALS INC., JOHNSON & JOHNSON, LUITPOLD PHARMACEUTICALS INC., PHARMACOSMOS A/S and PIERIS, among others.
Reasons to Purchase this Report
• Current and future iron deficiency anemia therapy market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3-month analyst support, along with the Market Estimate sheet in excel
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Rising Cases of Haemodilution in Pregnancy
6.1.2 High Prevalence of Anemia
6.2 Market Restraints
6.2.1 Stringent Regulatory Guidelines
6.2.2 Adverse Effects
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Type of Therapy
7.1.1 Oral Iron Therapy
7.1.2 Parenteral Iron Therapy
7.1.3 Red Blood Cell Transfusion
7.1.4 Others
7.2 By End User
7.2.1 Hospitals
7.2.2 Clinics
7.2.3 Home Healthcare
7.3 By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of the Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Allergen
9.2 Akebia Therapeutics
9.3 AMAG Pharmaceuticals
9.4 Keryx Biopharmaceuticals Inc.
9.5 Johnson & Johnson
9.6 Luitpold Pharmaceuticals Inc.
9.7 Pharmacosmos A/S
9.8 Pieris
**List Not Exhaustive
10. Future of the Market